GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CanBas Co Ltd (TSE:4575) » Definitions » NonCurrent Deferred Liabilities

CanBas Co (TSE:4575) NonCurrent Deferred Liabilities : 円0.00 Mil (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is CanBas Co NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

CanBas Co's non-current deferred liabilities for the quarter that ended in Dec. 2023 was 円0.00 Mil.

CanBas Co NonCurrent Deferred Liabilities Historical Data

The historical data trend for CanBas Co's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanBas Co NonCurrent Deferred Liabilities Chart

CanBas Co Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CanBas Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CanBas Co NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of CanBas Co's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


CanBas Co (TSE:4575) Business Description

Industry
Traded in Other Exchanges
N/A
Address
9 Toriyoko-cho, Shizuoka, JPN, 410-0891
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.

CanBas Co (TSE:4575) Headlines

No Headlines